Brief: Rain Therapeutics Announces Completion Of Enrollment In Phase 3 Mantra Trial For Milademetan In Liposarcoma
04/08/2022 14:40
Aug 4 (Reuters) - Rain Therapeutics Inc RAIN.O :
* RAIN THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
PHASE 3
MANTRA TRIAL FOR MILADEMETAN IN LIPOSARCOMA
* RAIN THERAPEUTICS INC - MANTRA TOPLINE DATA ANTICIPATED IN
1H
2023
Source text for Eikon: ID:nGNX9QRzpl
Further company coverage: RAIN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million